BioCryst Pharma's ORLADEYO leads HAE market growth, with strong financial performance and potential despite rising ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Porsche's margins plunged in the first quarter, the sportscar maker said on Tuesday, forcing it to cut its outlook due to ...

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ...

Operator: Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2025 Conference Call. At this time, ...

Many economists and Wall Street investors still expect the Fed will reduce rates two or three times this year.

Q1 earnings are due to be out on Monday, April 28. As of writing, that’s less than 24 hours away. Analysts expect a modest ...

Operator: Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2025 Conference Call. I am George, the Chorus ...

During the campaign Mr Trump referred to Meta as an “enemy of the people”. Many in his MAGA movement have accused America’s ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...